Evaluation of HFB200603 Monotherapy and Combination with Tislelizumab in Patients with Advanced Solid Tumors

The primary objective of this study is to evaluate the efficacy and safety of **HFB200603** as a monotherapy and in combination with **Tislelizumab** in patients with **advanced solid tumors**. This is clinically relevant as it aims to explore potential therapeutic options for individuals with these challenging malignancies, where current treatment options may be limited or ineffective.

The clinical trial involves a total of **39 participants** diagnosed with **advanced solid tumors**. The study population includes both male and female subjects, with an age range spanning from young adults to older adults. Participants were selected to ensure a diverse representation of the general population, including vulnerable groups. The trial does not specify particular lifestyle considerations such as diet or physical activity. The sponsor has not provided detailed information regarding the main objective or specific inclusion criteria for the study.

The clinical trial is designed to evaluate the safety and efficacy of **HFB200603** as a single agent and in combination with **Tislelizumab** in patients with **advanced solid tumors**. This study is structured as a Phase 1 trial, employing a randomized, double-blind, and controlled methodology to ensure the reliability and validity of the results. The trial is expected to commence recruitment on July 24, 2023, and is projected to conclude by September 13, 2025, encompassing a total duration of approximately two years.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria will be assessed. This initial visit is crucial for determining participant suitability based on predefined inclusion and exclusion criteria. Following successful screening, participants will be enrolled in the study and will attend regular follow-up visits. These visits are designed to monitor the participants' health status, assess the treatment's effects, and ensure adherence to the study protocol. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to gather comprehensive data on the treatment outcomes.

The expected length of participant involvement will vary depending on individual response to treatment and the specific protocol requirements. However, participants are generally anticipated to remain in the study for the duration of the trial unless specific conditions necessitate early termination. Such conditions may include adverse reactions to the treatment, withdrawal of consent, or any other medical or personal reasons deemed significant by the study investigators. The trial's design and procedures are meticulously crafted to uphold the highest standards of scientific rigor and ethical responsibility, ensuring the safety and well-being of all participants throughout the study period.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. The absence of these details suggests that the trial documentation may be incomplete or that such information is not applicable to this particular study.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on July 24, 2023, with an estimated completion date of September 13, 2025. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize various parameters such as **biomarker** levels or symptom improvement scores to gather initial efficacy data. The methods and schedule for measuring, collecting, and analyzing these parameters are not specified, but they generally involve validated scales, laboratory tests, or patient-reported outcomes at predetermined timepoints. The trial's design and execution will adhere to standard clinical trial protocols to ensure the reliability and validity of the efficacy assessments.